Sprache auswählen
TrkB
TrkB Molekülinformation
| Englischer Name | Neurotrophic tyrosine kinase receptor type 2 | Anzahl der inverkehr gebrachten Arzneimittel | 4 |
| Anzahl der klinischen Arzneimittel | 9 | Target-Alias | EC:2.7.10.1，EC 2.7.10，Tropomyosin-related kinase B，Trk-B，GP145-TrkB，NTRK2，Neurotrophic Receptor Tyrosine Kinase 2，Neurotrophic Tyrosine Kinase Receptor Type 2，TRKB，Neurotrophic Tyrosine Kinase， Receptor， Type 2，BDNF-Tropomyosine Receptor Kinase B，BDNF/NT-3 Growth Factors Receptor，Tyrosine Kinase Receptor B，TrkB Tyrosine Kinase，EC 2.7.10.1，EIEE58，OBHD，Receptor， trkB |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Neurotrophic tyrosine kinase receptor type 2 |
| Target-Alias | EC:2.7.10.1，EC 2.7.10，Tropomyosin-related kinase B，Trk-B，GP145-TrkB，NTRK2，Neurotrophic Receptor Tyrosine Kinase 2，Neurotrophic Tyrosine Kinase Receptor Type 2，TRKB，Neurotrophic Tyrosine Kinase， Receptor， Type 2，BDNF-Tropomyosine Receptor Kinase B，BDNF/NT-3 Growth Factors Receptor，Tyrosine Kinase Receptor B，TrkB Tyrosine Kinase，EC 2.7.10.1，EIEE58，OBHD，Receptor， trkB |
| Anzahl der inverkehr gebrachten Arzneimittel | 4 |
| Anzahl der klinischen Arzneimittel | 9 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
TrkB Produktliste
- Attribut
Protein (3)Cell (2)
- Produktbibliothek
Online (5)
- Spezies
Human (5)
- Etikett
Fc Tag (1)His Tag (1)Tag Free (1)His Tag & Avi Tag (1)- (1)
- Marker
Unconjugated (2)- (2)Biotin-labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
CHEK-ATF289 |  Human | HEK293 | Human TrkB (Luc) HEK293 Reporter Cell |  |  In den Warenkorb legen | ||
CHEK-ATP082 | Human | HEK293 | HEK293/Human TrkB Stable Cell Line | | In den Warenkorb legen | ||
NT2-H5228 | Human | HEK293 | Human TrkB / NTRK2 Protein, His Tag |  |  |  | In den Warenkorb legen |
NT2-H5254 | Human | HEK293 | Human TrkB / NTRK2 Protein, Fc Tag |  | | | In den Warenkorb legen |
NT2-H82E3 | Human | HEK293 | Biotinylated Human TrkB / NTRK2 Protein, His,Avitag™ (MALS verified) |  | | | In den Warenkorb legen |
Gesamtmenge5
- 1
TrkB Molekülhintergrund
This gene encodes a member of the neurotrophic tyrosine receptor kinase(NTRK)family.This kinase is a membrane-bound receptor that upon neurotrophin binding,phosphorylates itself and members of the MAPK pathway.Signalling through this kinase leads to cell differentiation.Mutations in this gene have been associated with obesity and mood disorders.
TrkB Molekülalias
NTRK2,TRKB,GP145-TrkB
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Prostatic Neoplasms; Neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Solid tumours; Skin Melanoma; Bone metastases; Pancreatic Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Gallbladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
| FCN-011 | FCN-011 | Phase 2 Clinical | Fochon Pharmaceuticals Ltd | Solid tumours | Details |
| ACD-856 | ACD-856 | Phase 1 Clinical | Alzecure Pharma Ab | Alzheimer Disease; Cognition Disorders | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| FB-1001 | FB_-1001; FB-1001; FB1001 | Phase 1 Clinical | 4b Technologies (Suzhou) Ltd | Optic Neuropathy, Ischemic; Optic Nerve Diseases; Glaucoma; Glaucoma, Angle-Closure | Details |
| 1-D-228 | 1D228; 1-D-228 | Phase 1 Clinical | Guangdong Lion Medical Research Institute Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| BrAD-R13 | BrAD-R13; BrADR13 | Phase 1 Clinical | Alzheimer Disease | Details | |
| PBI-200 | PBI-200 | Phase 1 Clinical | Pyramid Biosciences | Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Japan | Carcinoma, Non-Small-Cell Lung | Chugai Pharmaceutical Co Ltd | 2019-06-18 | Breast Neoplasms; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Lymphoproliferative Disorders; Colorectal Neoplasms; Sarcoma; Brain Neoplasms; Solid tumours; Cholangiocarcinoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Neoplasms; Salivary Gland Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Hematologic Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
| Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | United States | Solid tumours | Bayer Healthcare Pharmaceuticals Inc | 2018-11-26 | Glioma; Urinary Bladder Neoplasms; Histiocytosis, Langerhans-Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Histiocytic Sarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Multiple Myeloma; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Lung Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Melanoma; Uterine Cervical Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Ependymoma; Fibrosarcoma; Rhabdomyosarcoma; Medulloblastoma; Leukemia; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Colonic Neoplasms; Central Nervous System Neoplasms | Details |
| Repotrectinib | BMS-986472; ZL-2308; TPX-0005 | Approved | Turning Point Therapeutics Inc | 奥凯乐, Augtyro | United States | Carcinoma, Non-Small-Cell Lung | Bristol-Myers Squibb Company | 2023-11-15 | Solid tumours; Neoplasms; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main